AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05067530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor
Study NCT05067530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT05067530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Chemotherapy
Study NCT05067530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT05796388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: Both groups will receive standard of care linaclotide 290 mcg.
Study NCT05796388 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: Both groups will receive standard of care linaclotide 290 mcg.
Study NCT04143581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg/die for 28 days
Study NCT05295264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate exercise program
Description: Exercise program All sessions will begin with a warm-up of 7-8 minutes composed of mild movements and joint mobility of upper and lower limbs exercises. Then a central part of 35-40 minutes, four types of activities will be included (aerobic work, muscle strengthening, coordination/balance tasks, pelvic floor exercises), finally a section of flexibility, relaxation, and final talk (comments and sharing) will be performed (12-15 minutes).~Healthy lifestyle advise This intervention consists of providing guidelines and videos with advice on healthy habits throughout the pregnancy process. This type of content will be related to daily physical activity, food recommendations, and fundamental exercises to perform during pregnancy.
Study NCT05067530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Chemotherapy
Study NCT05367518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Streptococcus salivarius K12 Fast Melt Powder 1 Billion colony forming units /g)
Description: Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable tablet (lozenge) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT05367518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Streptococcus salivarius K12 Fast Melt Powder 100 Million colony forming units /g)
Description: Probiotic Streptococcus salivarius K12 products are commercially available in traditional formats such as chewable table (lozenges) for local delivery in the oral cavity to provide oral health benefits. In this study, a Fast Melt Powder formulation will be evaluated for its potential of delivering probiotic Streptococcus salivarius K12 to the oral cavity.
Study NCT06109337 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: drow blood
Description: Participants will be taken peripheral blood about 5 ml
Study NCT04463446 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of the CHD app
Description: Use of the CHD app
Study NCT04463446 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse-led intervention
Description: Teaching session with clinic nurse
Study NCT05404607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fascial distortion method with neuromuscular inhibition technique
Description: 27 participants will receive FDM with INIT followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
Study NCT05404607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascial distortion method
Description: 27 participants will receive FDM followed by neural mobilization for a total of 20 to 30 minutes, 3 times per week on alternate days for 6 weeks.
Study NCT06398821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: G3P-01
Description: Nutritional supplement to promote healthy aging
Study NCT06398821 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05051202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugars from Fiber
Description: Proprietary blend of Sugars from Fiber baked into 50 g flapjack
Study NCT05051202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistant Maltodextrin
Description: Resistant Maltodextrin baked into 50 g flapjack
Study NCT06046365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lymphoscintigraphy
Description: lymphoscintigraphy
Study NCT06046365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: circumference measurement
Description: circumference measurement
Study NCT06046365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: sonography
Description: B-mode sono and elastography
Study NCT06046365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DXA body composition analysis
Description: DXA body composition analysis
Study NCT04848480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin icodec
Description: insulin icodec 700 units/mL, subcutaneously (under the skin), solution for injection once weekly
Study NCT04848480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: insulin degludec 100 units/mL, subcutaneously (under the skin), solution for injection once daily
Study NCT04848480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
Study NCT04848480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: insulin aspart 100 units/mL, subcutaneously (under the skin), solution for injection daily
Study NCT06425510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viviendo las Ventajas de la Asistencia Tecnológica
Description: It comprises 2-hours small group sessions of 8-10 participants, once a week, for six weeks of participatory discussions, experiential learning, multimodal instructions, and demonstration and practice with selected ATDs. The content of the VIVE-AT weekly sessions is as follows: Week 1 - Introduction to ATDs, funding and resources; Week 2 - ATDs for self-care and toilet use; Week 3 - ATDs for mobility; Week 4 - ATDs for dressing; Week 6 - ATDs for cooking and home tasks. Each session is designed with the following components: monitoring of participants\&#39; weekly goals, providing information on ATDs, resources, and services, reflection on the advantages and disadvantages of using these ATDs, hands-on practice with selected ATDs, goal setting, and addressing barriers to using ATDs. Group sessions will incorporate visual aids, including modeling and videos of older individuals using ATDs accessed through an AT web app in a tablet provided by this project.
Study NCT06425510 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention calls
Description: Ten minutes attention calls, once a week for six weeks to the waitlist control participants will offer general health advice on topics like nutrition, exercise, sleep, stress, and social connections. These calls emphasize participant well-being without touching upon the specific VIVE-AT content, maintaining a clear distinction from the intervention group.
Study NCT05040698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Open label Fostamatinib
Study NCT04554459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 MG Oral Tablet
Description: ponatinib plus reduced-intensity chemotherapy in first-line treatment of Adult Ph+ ALL
Study NCT06251622 — intervention group
Intervention type: OTHER
Intervention: Volumetric ultrasound of the quadriceps and fitting of an accelerometer
Description: The research procedure will simply involve a volumetric ultrasound of the quadriceps and the fitting of an accelerometer (watch worn on the wrist) for one week (collection of usual physical activities).
Study NCT05434494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.
Study NCT05434494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Remimazolam is injected for 30 seconds and the experimental dose will be determined according to the biased coin design up-and-down sequential method.~If loss of consciousness is successful, the dose of the next intravenous dose of the next study subject will be reduced from the previous dose with a probability of 1/19 or the same as the previous dose with a probability of 18/19.
Study NCT05434494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifantanil
Description: 25cc infusion drug will be prepared (labeled as test drug) and infused with TCI mode. The target effect site concentration is 2.0 ng/ml.
Study NCT06156852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based stress reduction group
Description: Mindfulness-based stress reduction (MBSR) group interventions were implemented for eight weeks.
Study NCT06156852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral-based stress reduction group
Description: Cognitive behavioral-based stress reduction group interventions were implemented for eight weeks.
Study NCT04847570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music session
Description: Non-clinical intervention only, and no change to clinical care or treatment. Participants will have 10 minutes of undisturbed rest, followed by a supervised music-listening session of up to 40 minutes, ending with another 10-minute rest period.
Study NCT01153204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy
Study NCT01153204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Psychotherapy plus Sildenafil citrate
Study NCT01153204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Study NCT05232084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + Fentanyl
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
Study NCT04280016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will participate in an exercise session with non-weight-bearing exercise that the participant is able to perform with off-loading (e.g. total contact cast) intact. They will also be instructed in a home exercise program so that exercise can be performed three days per week with no more than two days between sessions. These participants will also receive standard wound care with off-loading.
Study NCT05321459 — intervention group
Intervention type: OTHER
Intervention: Neurological prognosis
Description: In usual practice, in intensive care unit, evaluating the neurological prognosis of comatose patients after cardiac arrest requires a multimodal approach combining standardized clinical examination, serum biomarkers, imaging and classically electrophysiological examinations (among them auditive evoked potentials or AEP).~An algorithm (PRECOM tool) which has been previously developed from the signal extracted from AEP allows to visually classify the patients after processing signal by the algorithm in a cluster of points with a high specificity into good neurological prognosis and bad neurological prognosis.~The AEP signals recorded in the 1st and 2nd week of patient inclusion are to be collected by the neurophysiologist. At the end of the patient's participation in the study, these data will be encrypted, anonymized and transmitted to the mathematician to be processed by the PRECOM tool.
Study NCT04912544 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive Ventilation Mask Microphone
Description: Noninvasive Ventilation Mask Microphone is turned on to enhance speech intelligibility during the intervention portion of the crossover feasibility study
Study NCT06451367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuromuscular programm
Description: neuromuscular programm during 12 weeks (3 times a week, 10 minutes each time)
Study NCT05198076 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Frequency Repetitive Transcranial Magnetic Stimulation
Description: The High Frequency repetitive TMS will be delivered to the scalp over the primary motor cortex contralateral to the more affected side using a MAGSTIM rapid2 machine (Model P/N 3576-23-09, MAGSTIM Company LTD, UK) connected with a figure - of- eight shaped coil. Each patient will receive 12 sessions over four weeks. Position of the coil will be adjusted to find the optimal scalp position and the location of stimulation that will be marked to maintain consistency among sessions. The session will consist of 24 trains of 50 stimuli each delivered at five Hz. The procedure will be conducted with the patients in the ''On'' state (75 min. after medications)
Study NCT04972188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYIL1 Capsule
Description: NLRP3 inflammasome inhibitor
Study NCT06306924 — intervention group
Intervention type: RADIATION
Intervention: Radiation therapy
Description: Subjects with metastatic cancer receive radiation therapy.
Study NCT05496985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs) and Coma Recovery Scale-Revised (CRS-R)
Study NCT05003141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSB202
Description: PSB202 is an antibody combination product comprised of two full-length monoclonal antibodies, PSB102 and PSB 107, respectively targeting CD20 and CD37. PSB202 is manufactured to work as a single product.
Study NCT05531968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMI2006
Description: IM
Study NCT05531968 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: IM
Study NCT04814472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: Randomized to active product.
Study NCT06294041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Restriction Therapy (SRT)
Description: SRT is a manualised, adaptive, behavioural insomnia intervention that is a key active ingredient within multi-component CBT-I. Our SRT protocol involves standardising and (where required) limiting a patient's time in bed with the aim of increasing homeostatic sleep pressure, over-riding cognitive and physiological arousal, and strengthening circadian control of sleep. Those randomised to the SRT arm will receive two online sessions supported by two telephone calls over a 4-week intervention phase. The intervention will be delivered by trained research nurses
Study NCT06294041 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene Education (SHE)
Description: SHE will be delivered via a booklet that provides information about lifestyle changes (e.g., reducing exercise in the evening, light snack before bedtime, reducing caffeine) and changes to the bedroom environment (e.g., dark room, comfortable mattress, optimal room temperature). Patients in the SHE condition will be instructed to implement the SHE advice over a 4-week period. One week after randomisation to SHE, the RA will telephone patients to check they understand the SHE advice and answer any questions they may have. SHE has successfully been used as a control condition in other trials evaluating SRT and does not have any therapeutic benefit for individuals with insomnia but is often part of usual care, so is a credible alternative to SRT.
Study NCT04871763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retainers' Cleansing with Geldis®
Description: Patients will clean their essix retainers with Geldis® using a toothbrush every night for 2 months.
Study NCT04871763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retainers' Cleansing with tablets
Description: Patients will leave their essix retainers in a glass with water and Polident tablets every night for 2 months.
Study NCT04871763 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retainers' cleansing with water
Description: Patients will brush their essix retainers with a toothbrush under water every night for 2 months.
Study NCT06431165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: After confirming patient history, type of operation and patient group allocation, standard ASA monitoring will be attached to the patient then the I.V induction of anesthesia will be commenced using standard doses of Propofol \&Tracrium in addition to 1 μg/kg Fentanyl and 1 ml/10 kg from the bolus Lidocaine syringe followed after 3 minutes by endotracheal intubation, then the Lidocaine infusion Syringe will be attached to a separate I.V line at an infusion rate of 1 ml/10 kg/h. The patient will receive 1 gm of I.V paracetamol and the surgery will be allowed to proceed.
Study NCT06214169 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cisatracurium Besylate
Description: Addition of cisatracurium to plain lignocaine for IVRA.
Study NCT06214169 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lignocaine
Description: Plain Lignocaine for IVRA
Study NCT05854823 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: dose-reduced radiotherapy
Description: Patients receive 50Gy/25F, 2Gy/F QD, five days a week for 5 weeks
Study NCT04259983 — intervention group
Intervention type: OTHER
Intervention: Maximal exercise test
Description: The maximal exercise test will be performed on an electronically braked bicycle ergometer.
Study NCT04259983 — intervention group
Intervention type: OTHER
Intervention: Endothelial dysfunction assessment
Description: Endothelial dysfunction will be determined by blood samples. Blood samples will be collected and analyzed for the responses of ICAM-1, VCAM-1, E-Selectin, VEGF, ET-1.
Study NCT04718740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluzoparib
Description: Group A: Caffeine, vitamin K, warfarin, omeprazole, and midazolam with or without fluzoparib Group B: Repaglinide and bupropion with or without fluzoparib
Study NCT06122753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preemptive TIPS
Description: The TIPS procedure should be performed within 72 hours after the initial endoscopic examination or treatment. An 8 mm Viatorr stent will be used for TIPS establishment. The aim will be to reduce the portal pressure gradient below 12 mm Hg. Embolization, either with coils or glue, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices. After TIPS, anticoagulation will not be used as a rule but is allowed if the attending physician thinks that it is warranted.
Study NCT06122753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard second prophylaxis
Description: Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (carvedilol) will be started with an initial dose of 6.25 mg, the dose of propranolol will be increased to 12.5 mg.~The second elective session of endoscopic band ligation will be performed within the first 28 days after the initial endoscopic treatment. The following sessions will be performed at 28 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed.
Study NCT06065904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrilect
Description: This intervention involves a comprehensive approach that includes a thorough nutritional assessment and individualized nutrition plan for children with cerebral palsy (CP) and Autism Spectrum Disorder (ASD), addressing their unique dietary needs and challenges. It encompasses nutritional counseling, dietary modifications when necessary, and seamless integration with other therapies, including speech therapy and psychological consultation. The overarching goal is to optimize growth, muscle function, and overall well-being in these children by providing tailored nutritional support alongside a holistic care approach.
Study NCT04259983 — intervention group
Intervention type: OTHER
Intervention: Arterial stiffness assessment
Description: Arterial stiffness, oscillometric pulse wave velocity (PWV) and augmentation index will be evaluated by recorded brachial pulse waves with automatically with the oscillometric device.
Study NCT04594707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRM-151 (Zinpentraxin Alfa)
Description: Cohort A: Participants will receive three loading doses of open-label PRM-151 on days 1, 3, and 5, then one infusion every 4 weeks (Q4W). 10 mg/kg of PRM 151 will be administered by intravenous (IV) infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks.~Cohort B: Participants previously randomized to the placebo in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. All three doses will contain PRM-151. Participants previously randomized to the treatment arm in WA42293 will receive study medication in the three loading doses on days 1, 3 and 5 in a blinded fashion. One of the three doses will contain PRM-151, whereas two doses will contain placebo.